HLTH is the first pure-play ETF focused on AI’s transformation of healthcare.

Tema ETFs ("Tema"), a leader in institutional-quality and actively managed exchange-traded funds, today announced the launch of the Tema Healthcare AI ETF (HLTH).

HLTH was developed to invest in one of AI’s largest and most consequential applications: improving healthcare. U.S. healthcare spending is forecast to approach $9 trillion by 2034, representing more than 20% of GDP.¹ Yet healthcare accounted for just 8.9% of the S&P 500 as of June 30,² leaving AI’s potential to elevate the sector underappreciated by the market.

That potential is rapidly moving from research to implementation. DeepMind’s AlphaFold, an AI model that predicts protein structures, won the 2024 Nobel Prize in Chemistry and is already used by more than 2 million researchers,³ demonstrating how quickly a scientific breakthrough can become a widely adopted research tool. Anthropic has said AI could compress a century of biological progress into a decade, while healthcare and biopharma together represent the third-largest category of global private AI investment.

As the AI investment cycle broadens beyond the semiconductor-led infrastructure buildout, healthcare stands as one of the largest markets for adoption. HLTH offers a pure-play way to invest in that shift, targeting companies at the leading edge of drug discovery, diagnostics, clinical applications such as robotics, and technologies that improve patient care.

Healthcare innovation is complex, highly specialized, and marked by significant scientific and clinical risk, which Tema believes warrants an expert-led approach. HLTH is managed by Dr. David Song, MD, PhD, CFA, a Yale and Penn-trained physician with more than two decades of healthcare investing experience.

"AI has the potential to improve nearly every aspect of healthcare, from research and diagnosis to treatment and care delivery," said Dr. David Song, Investment Partner and Portfolio Manager of HLTH. "In drug development, it can help researchers identify better candidates faster and improve the odds of clinical success. In clinical settings, it can enable earlier detection, greater precision, and more efficient care. We believe navigating these opportunities requires expertise and an active approach to identifying advances that can deliver better outcomes for patients, providers, and investors alike."

Fund Facts

Ticker	HLTH
Exchange	NASDAQ
CUSIP	87975E768
Gross Expense Ratio	0.75%
Listing Date	July 21, 2026
Fund Webpage	temaetfs.com/HLTH

About Tema ETFs

Tema builds institutional-quality ETF solutions for a range of market environments, spanning high-conviction growth opportunities, durable core exposures, and alternatives. Founded in 2022, Tema is led by veterans of the ETF and global asset management industry, and backed by Index Ventures, Accel Partners, Zinal Growth, and over a dozen financial services CEOs and fintech founders.

HLTH Top 10 Holdings (as of Jul 21)

Security Name	Weight
10X GENOMICS INC	5.40%
CYTOKINETICS INC	5.19%
ILLUMINA INC	4.96%
INTUITIVE SURGICAL INC	4.60%
VERTEX PHARMACEUTICALS INC	4.50%
REVOLUTION MEDICINES INC	4.48%
TWIST BIOSCIENCE CORP	4.06%
COGENT BIOSCIENCES INC	4.01%
DEXCOM INC	4.01%
NATERA INC	3.96%

As of Jul 21, 2026. For all current holdings, visit the HLTH fund webpage.

Sourcing

¹ Centers of Medicare & Medicaid Services, NHE Fact Sheet, as of Jul 2026

² Bloomberg, Jun 2026

³ AI Magazine, "AlphaFold 2: The AI System That Won Google a Nobel Prize," Oct 2024

Disclosures

Institutional-quality qualification is premised on the >90% estimated institutional adoption of Tema's funds to date as of Jul 21, 2026 and the institutional background and track record of Tema's investment team.

Carefully consider the Fund's investment objectives, risk factors, charges and expenses before investing. This and additional information can be found in the Fund's prospectus or summary prospectus, which may be obtained by visiting www.temaetfs.com. Read the prospectus carefully before investing.

Investing involves risk including possible loss of principal. There is no guarantee the fund's investment strategy will be successful.

Sector Focus Risk: The Fund may invest a significant portion of its assets in one or more sectors and thus will be more susceptible to the risks affecting those sectors than funds that have more diversified holdings across a number of sectors. The Fund anticipates that it may be subject to some or all of the risks described below.

Healthcare Sector Risk: To the extent the Fund focuses on the healthcare sector, the Fund may be more susceptible to the particular risks that may affect companies in the healthcare sector than if it were invested in a wider variety of companies in unrelated sectors. The profitability of companies in the healthcare sector may be adversely affected by the following factors, among others: extensive government regulations, restrictions on government reimbursement for medical expenses, rising costs of medical products and services, pricing pressure, an increased emphasis on outpatient services, changes in the demand for medical products and services, a limited number of products, industry innovation, changes in technologies and other market developments. The expiration of a company’s patents may adversely affect that company’s profitability. Healthcare companies are subject to competitive forces that may make it difficult to raise prices and, in fact, may result in price discounting. Many new products in the healthcare sector may be subject to regulatory approvals. The process of obtaining such approvals may be long and costly, and such efforts ultimately may be unsuccessful. Companies in the healthcare sector may be thinly capitalized and may be susceptible to product obsolescence.

Information Technology Sector Risk: Information technology companies face intense competition, both domestically and internationally, which may have an adverse effect on their profit margins. Like other technology companies, information technology companies may have limited product lines, markets, financial resources or personnel. Companies in the information technology sector are heavily dependent on patent and intellectual property rights. The loss or impairment of any of these rights may adversely affect the profitability of these companies or the Fund’s performance.

Tema ETFs LLC serves as the investment adviser to Tema Healthcare AI ETF (the "Fund"), and Tidal Investments LLC serves as a sub-adviser to the Fund. The Fund is distributed by Vigilant Distributors, LLC, which is not affiliated with Tema ETFs LLC nor Tidal Investments LLC. Check the background of Vigilant Distributors, LLC on FINRA’s BrokerCheck.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260721480281/en/

Media Contact

Steve Munroe

Tema ETFs

PR@temaetfs.com